No Data
No Data
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
12 Health Care Stocks Moving In Monday's Intraday Session
Roth MKM Sticks to Their Buy Rating for Aptevo Therapeutics (APVO)
Express News | Roth MKM Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $8
Aptevo Therapeutics Analyst Ratings
No Data
No Data